#50 - Frank Bedu-Addo, President and CEO at PDS Biotechnology Corporation
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
#50 - Frank Bedu-Addo, President and CEO at PDS Biotechnology Corporation
-
Narrated by:
-
By:
About this listen
Join us on the latest episode! Our Guest: Frank Bedu-Addo, President and CEO at PDS Biotechnology Corporation.
What you'll get out of this episode:
- PDS Biotechnology targets the key limitations of CAR T and cancer vaccine therapies using lipid nanoparticle-based immunotherapy.
- Their lead candidate, PDS0101, demonstrated over 2x improvement in survival for HPV-positive head and neck cancer.
- The platform technology shows consistent efficacy across multiple independent Phase 2 trials.
- Late-stage clinical programs focus on HPV16+ head and neck cancer, with additional trials for colorectal, prostate, and MUC1+ cancers.
To Learn More About Our Guest And Their Company:
Guest LinkedIn https://www.linkedin.com/in/frank-bedu-addo-4797947/
Company LinkedIn https://www.linkedin.com/company/pds-biotechnology-corporation/
Website https://www.pdsbiotech.com/
Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.